Print this page
-
Phase 1/1b Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer.
Protocol: 032204Principal Investigator:
- Malcolm Mattes (New Jersey Medical School)
Applicable Disease Sites: Lip, Oral Cavity and Pharynx
Larynx -
NRG-BN012, A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases
Protocol: 142302Principal Investigator:
- Nicholas DeNunzio MD, PhD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Brain and Nervous System -
NRG-GU012: Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI)
Protocol: 082305Principal Investigator:
- Lara Hathout MD (Rutgers University)
Applicable Disease Sites: Kidney -
CTEP #10512: A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination with Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer
Protocol: 032309Principal Investigator:
- Salma Jabbour M.D. (Rutgers University)
Applicable Disease Sites: Lung -
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer.
Protocol: 032403Principal Investigator:
- Dylan Roden (New Jersey Medical School)
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC).
Protocol: 112405Principal Investigator:
- Scott Moerdler M.D. (Rutgers University)
Applicable Disease Sites: Lip, Oral Cavity and Pharynx